Financial Statements of

## ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

(FORMERLY THE ARTHRITIS SOCIETY/ LA SOCIÉTÉ D'ARTHRITE)

And Independent Auditor's Report thereon

Year ended March 31, 2023



KPMG LLP Vaughan Metropolitan Centre 100 New Park Place, Suite 1400 Vaughan ON L4K 0J3 Canada Tel 905-265-5900 Fax 905-265-6390

### INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Arthritis Society Canada/Société d'Arthrite du Canada

### **Qualified Opinion**

We have audited the financial statements of Arthritis Society Canada/Société d'Arthrite du Canada (formerly The Arthritis Society/La Société D'arthrite) (the Entity), which comprise:

- the statement of financial position as at March 31, 2023
- the statement of financial activities for the year then ended
- the statement of changes in resources for the year then ended
- the statement of cash flows for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies

(Hereinafter referred to as the "financial statements").

In our opinion, except for the possible effects of the matter described in the **"Basis for Qualified Opinion"** section of our auditor's report, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at March 31, 2023, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

#### **Basis for Qualified Opinion**

In common with many charitable organizations, the Entity derives revenue from support from the public, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, verification of this revenue was limited to the amounts recorded in the records of the Entity.

Therefore, we were not able to determine whether any adjustments might be necessary to:

- the current assets reported in the statements of financial position as at March 31, 2023 and March 31, 2022
- the contributions and deficiency of revenue over expenses reported in the statements of financial activities for the years ended March 31, 2023 and March 31, 2022



#### Page 2

- the resources, at the beginning and end of the year, reported in the statements of changes in resources for the years ended March 31, 2023 and March 31, 2022
- the deficiency of revenue over expenses reported in the statements of cash flows for the years ended March 31, 2023 and March 31, 2022.

Our opinion on the financial statements for the year ended March 31, 2022 was qualified accordingly because of the possible effects of this limitation in scope.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our auditor's report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

# Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.



### Page 3

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

#### We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
  - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



### Page 4

Communicate with those charged with governance regarding, among other
matters, the planned scope and timing of the audit and significant audit findings,
including any significant deficiencies in internal control that we identify during our
audit.

Chartered Professional Accountants, Licensed Public Accountants

Vaughan, Canada

KPMG LLP

June 16, 2023

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Statement of Financial Position

March 31, 2023, with comparative information for 2022

	2023	2022
Assets		
Current assets:		
Cash	\$ 607,388	\$ 1,865,117
Restricted cash	32,744	71,378
Short-term investments (note 2(a))	1,395,930	1,558,149
Accounts receivable (note 16)	472,112	583,908
Prepaid expenses	751,712	612,553
	3,259,886	4,691,105
Long-term investments (note 2(b))	5,944,839	7,697,720
Capital assets (note 3)	2,085,507	1,892,856
	, ,	· · ·
	\$ 11,290,232	\$ 14,281,681
Liabilities and Resources  Current liabilities:  Accounts payable and accrued liabilities	\$ 1,056,384	\$ 2,055,423
Deferred revenue	660,973	1,127,103
Research awards payable (note 13)	1,169,187	1,705,332
	2,886,544	4,887,858
Deferred capital grants and donations (note 4)	676,367	530,621
Deferred contributions (note 5)	3,253,327	3,891,522
Deferred lease inducements (note 6)	50,803	111,768
	6,867,041	9,421,769
Resources	4,423,191	4,859,912
Commitments (notes 11 and 12)		
	\$ 11,290,232	\$ 14,281,681

See accompanying notes to financial statements.

On Nehalf of the Board:

Director

Director

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Statement of Financial Activities

Year ended March 31, 2023, with comparative information for 2022

	2023	2022
Revenue:		
Support from the public:		
Campaigns	\$ 13,708,479	\$ 11,689,816
Bequests and other planned giving	7,386,952	4,904,786
	21,095,431	16,594,602
Investment, rental and miscellaneous	2,153,518	1,808,456
Support from government departments and agencies	5,743,460	6,521,390
Total revenue	28,992,409	24,924,448
Expenses (note 15):		
Research	6,237,332	5,247,265
Programs and services	10,745,652	9,809,390
Building operation	745,588	668,474
Administration	2,860,071	2,324,635
7 tarimiotration	20,588,643	18,049,764
Cost of raising funds from the public (note 15)	8,364,359	7,447,313
Total expenses	28,953,002	25,497,077
Total expenses	20,933,002	20,491,011
Excess (deficiency) of revenue over expenses		
before the undernoted	39,407	(572,629)
Unrealized gain (loss) on investments	(481,128)	145,227
Deficiency of revenue over expenses	\$ (441,721)	\$ (427,402)

See accompanying notes to financial statements.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Statement of Changes in Resources

Year ended March 31, 2023, with comparative information for 2022

						2023	2022
					Invested in capital		
	Una	ppropriated	Eı	ndowments	assets	Total	Total
Resources, beginning of year	\$	1,135,598	\$	2,362,079	\$ 1,362,235	\$ 4,859,912	\$ 5,284,194
Deficiency of revenue over expenses		(212,828)		_	(228,893)	(441,721)	(427,402)
Additions to capital assets		(521,328)		_	521,328	_	_
Deferred capital grants and donations received		245,530		_	(245,530)	_	-
Endowment contributions and changes		(8,018)		13,018	-	5,000	3,120
Resources, end of year	\$	638,954	\$	2,375,097	\$ 1,409,140	\$ 4,423,191	\$ 4,859,912

See accompanying notes to financial statements.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Statement of Cash Flows

Year ended March 31, 2023, with comparative information for 2022

		2023		2022
Cash provided by (used in):				
Operating activities:				
Deficiency of revenue over expenses Items not affecting cash:	\$	(441,721)	\$	(427,402)
Amortization of deferred capital grants and donations		(99,784)		(59,331)
Amortization of deferred contributions		(1,617,238)		(1,587,584)
Amortization of deferred lease inducements		(60,965)		(60,964)
Amortization of capital assets		328,677		302,937
Change in unrealized loss (gain) on investments		481,128		(145,227)
Change in non-cash operating working capital (note 9)		(2,028,677)		2,704,578
		(3,438,580)		727,007
Financing activities:				
Deferred contributions received		979,043		1,212,196
Net endowment contributions and changes		5,000		3,120
Deferred capital grants and donations received		245,530		480,003
		1,229,573		1,695,319
Investing activities:				
Net purchase of investments		1,433,972		(2,240,855)
Net purchases of capital assets		(521,328)		(600,157)
		912,644		(2,841,012)
Decrease in cash		(1,296,363)		(418,686)
Cash, beginning of year		1,936,495		2,355,181
Cash end of year	\$	640,132	\$	1,936,495
·		•		
Represented by: Cash	\$	607 200	φ	1 06E 117
<b>3</b> .5	Ф	607,388	\$	1,865,117
Restricted cash		32,744		71,378
	\$	640,132	\$	1,936,495

See accompanying notes to financial statements.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements

Year ended March 31, 2023

Arthritis Society Canada/Société d'Arthrite du Canada (formerly The Arthritis Society/La Société D'arthrite) (the "Society") is incorporated without share capital under the Canada Corporations Act and was continued under the Canada Not-for-Profit Corporations Act in July 2013. The Society is a charitable organization registered under the Income Tax Act (Canada) and, as such, it is exempt from income taxes and is able to issue donation receipts for income tax purposes.

The mission of the Society is fight the fire of arthritis with research, advocacy, innovation, information and support.

### 1. Significant accounting policies:

The financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations ("ASNPO") in Part III of the Chartered Professional Accountants of Canada Handbook.

#### (a) Basis of presentation:

These financial statements include the assets, liabilities, revenue and expenses of the regions and the National Office of the Society.

#### (b) Revenue recognition:

The Society follows the deferral method of accounting. Under the deferral method, contributions related to expenses of future periods are recorded as deferred contributions and are recognized as revenue in the year in which the related expenses are incurred. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Endowment contributions are shown on the statement of changes in resources.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 1. Significant accounting policies (continued):

### (c) Allocation of expenses:

Expenses are recorded and reported by programs and services. Certain employees perform a combination of program, fundraising and administrative functions; as a result, salaries and benefits are allocated based on time dedicated to the functional activities. Other costs, including amortization of capital assets and executive office and administrative support, are allocated to the programs and services that benefit from the activities. Such allocations are reviewed regularly by management.

### (d) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Equity instruments that are quoted in an active market are subsequently measured at fair value. All other financial instruments are subsequently recorded at cost or amortized cost unless management has elected to carry the instruments at fair value. The Society has elected to carry any such financial instruments at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

Financial assets are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, the Society determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset. If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount the Society expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial carrying value.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 1. Significant accounting policies (continued):

#### (e) Resources balances:

Unappropriated resources record the general activities of the Society.

Invested in capital assets reflect that portion of the Society's resources that relate to capital assets. These resources will increase for capital asset purchases, reductions in capital lease obligations, amortization of deferred capital grants and donations directly related to capital assets, and will be reduced by amortization charges, the net book value of capital asset disposals, increases in capital lease obligations and increases in deferred capital grants and donations.

Endowment funds are externally restricted donations received by the Society where the endowment principal is required to be maintained intact. The investment income generated from these endowments is to be used in accordance with the various purposes established by the donors. The Society ensures that all funds received with a restricted purpose are expended for the purpose for which they were provided.

#### (f) Research awards payable:

These financial statements reflect grants made during the year, which became effective at different dates during the year. The balance of these grants remaining payable at year end is included as research awards payable on the statement of financial position.

#### (g) Capital assets:

Purchased capital assets are recorded at cost. Donated capital assets are recorded at fair value at the date of contribution. Repairs and maintenance costs are charged to expense. Betterments which extend the estimated life of an asset are capitalized.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 1. Significant accounting policies (continued):

Amortization is provided on a straight-line basis over the estimated useful lives of the assets and is recorded beginning in the month of acquisition as follows:

Buildings5%Computer equipment and software33.33%Furniture and equipment20%Leasehold improvementsOver term of lease

Capital assets are written down to fair value or replacement cost to reflect partial impairments when conditions indicate that the assets no longer contribute to the Society's ability to provide services, or that the value of future economic benefits or service potential associated with the capital assets are less than their net carrying amounts.

#### (h) Deferred capital grants and donations:

Government grants and donations received for the purpose of capital purchases are deferred and amortized over the expected useful life of the asset to which the grants and donations relate.

#### (i) Deferred lease inducements:

Deferred lease inducements represent leasehold improvements on account of capital expenditures financed by the landlord. These lease inducements are amortized on a straight-line basis over the term of the lease and are recorded as a reduction in rental expense.

#### (j) Contributed services:

Volunteers contribute countless hours each year to assist the Society in achieving its mission. Because of the difficulty in determining their fair value, contributed services are not recognized in the financial statements.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 1. Significant accounting policies (continued):

#### (k) Use of estimates:

The preparation of financial statements in conformity with ASNPO requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Actual results could differ from those estimates.

#### 2. Investments:

#### (a) Short-term investments include:

	2023	2022
Fixed income Money market Equity pooled fund Global equities and pooled funds	\$ 1,002,189 374,328 10,970 8,443	\$ 1,002,047 516,396 20,940 18,766
	\$ 1,395,930	\$ 1,558,149

Short-term fixed-income funds have maturity dates of less than a year from the statement of financial position dates and bear interest at rates ranging from 0.5% to 5.00% (2022 - 0.01% to 0.52%).

During 2023, \$1,000,000 (2022 - \$1,000,000) guaranteed investment certificates ("GICs") were purchased on July 19, 2022, maturing on July 19, 2023 (2022 - May 7, 2021 matured on May 9, 2022), and bear interest from 3.95% to 4.08% (2022 - 0.52%).

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 2. Investments (continued):

#### (b) Long-term investments include:

	2023	2022
Fixed income Global equities and pooled funds Canadian equities	\$ 3,107,051 1,966,777 871,011	\$ 4,154,612 2,002,875 1,540,233
	\$ 5,944,839	\$ 7,697,720

Long-term investments consist of fixed income bonds with maturity dates greater than a year from the statement of financial position date and bearing interest at rates ranging from 0.50% to 8.29% (2022 - 0.05% to 8.05%), and Canadian and U.S. equities and investments in unit trusts.

During 2022, a \$1,000,000 GIC was purchased on May 7, 2021, matured on May 8, 2023 and bears interest at 0.80%.

### 3. Capital assets:

				2023	2022
		A	ccumulated	Net book	Net book
	Cost	а	mortization	value	value
Land	\$ 239,306	\$	_	\$ 239,306	\$ 239,306
Buildings	7,788,607		6,165,643	1,622,964	1,277,131
Computer equipment					
and software	696,872		604,225	92,647	153,860
Furniture and equipment	687,118		620,726	66,392	80,123
Leasehold improvements	733,631		669,433	64,198	142,436
•	,		,	,	,
	\$ 10,145,534	\$	8,060,027	\$ 2,085,507	\$ 1,892,856

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 4. Deferred capital grants and donations:

Deferred capital grants and donations represent restricted capital funding received to purchase capital assets. Grants and donations are amortized on the same basis as the capital asset to which they relate. Changes in the deferred capital grants and donations balances during the year are as follows:

	2023	2022
Balance, beginning of year Grants received	\$ 530,621 245,530	\$ 109,949 480,003
	776,151	589,952
Less amortization	99,784	59,331
Balance, end of year	\$ 676,367	\$ 530,621

#### 5. Deferred contributions:

Deferred contributions represent unspent resources, externally or internally restricted, for education, volunteer/community development, patient care, research purposes and restricted operating funds received in the current year or prior years that are related to subsequent periods. Changes in the deferred contribution balances during the year are as follows:

				2023	2022
		Patient			
	Education	care	Research	Total	Total
Balance, beginning of year Funds received Amount recognized as revenue	\$ 875,314 847,163 (470,393)	\$ 5,416 - (3,420)	\$ 3,010,792 131,880 (1,143,425)	\$ 3,891,522 979,043 (1,617,238)	\$ 4,266,910 1,212,196 (1,587,584)
Balance, end of year	\$ 1,252,084	\$ 1,996	\$ 1,999,247	\$ 3,253,327	\$ 3,891,522

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 6. Deferred lease inducements:

	2023	2022
Tenant inducements Less accumulated amortization	\$ 672,867 622,064	\$ 672,867 561,099
	\$ 50,803	\$ 111,768

### 7. Appropriated resources:

During 2023, the Board of Directors of the Society approved a transfer of nil (2022 - \$17,532) as included in interfund transfers on the statement of changes in resources from appropriated reserves to unappropriated reserves relating to the change in the Reserve Policy as outlined in note 16(c). In addition, during 2022, the Board of Directors restricted \$1,000,000 for the purpose of an Awareness Campaign. The restriction was subsequently released upon completion of the campaign during 2022.

#### 8. Annuity, life insurance and charitable remainder trust revenue:

As at March 31, 2023, the Society is the beneficiary of several annuities purchased by donors with original annuity contract amounts of \$137,500 (2022 - \$137,500). An annuity is established through an original donation of cash and the remaining donations being continuously invested. The cash donation and any realized beneficiary amounts are recorded as revenue when received.

The Society is also the beneficiary of several life insurance policies purchased by donors. Revenue relating to these policies is recorded on a cash basis. The total death benefit relating to these policies outstanding as at March 31, 2023 amounted to \$442,034 (2022 - \$442,034).

The Society is also the beneficiary of several charitable remainder trusts. The donations are recorded as revenue when the cash is received. The trust amounts outstanding as at March 31, 2023 amounted to nil (2022 - nil). During 2023, \$5,386 (2022 - \$5,025) was received in cash and included in Bequests and other planned giving.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 9. Change in non-cash operating working capital:

	2023	2022
Accounts receivable Prepaid expenses Accounts payable and accrued liabilities Deferred revenue	\$ 111,796 (139,159) (999,039) (466,130)	\$ 3,049,169 (256,552) 369,779 48,089
Research awards payable	(536,145)	(505,907)
	\$ (2,028,677)	\$ 2,704,578

#### 10. Pension plan:

Certain of the employees of the Society are members of Arthritis Society Canada Pension Plan (formerly The Arthritis Society Pension Plan) (the "Plan"), which is a defined contribution plan. Employer contributions made to the Plan during the fiscal year by the Society are reflected in the statement of financial activities and amounted to \$375,064 (2022 - \$380,106).

#### 11. Research commitments:

The Society has approved research commitments for future years for which the recipients must meet certain milestone reporting requirements in order to achieve funds release, as follows:

2024	\$ 6,039,225
2025	3,701,308
2026	1,397,067
	\$ 11,137,600

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 12. Commitments:

The Society has entered into several operating lease commitments for office premises and office equipment. The minimum annual lease payments are as follows:

2024	\$ 1,159,360
2025	209,851
2026	49,891
2027	40,942
	\$ 1,460,044

#### 13. Related party transactions:

During the year, \$140,000 (2022 - \$140,000) was awarded to universities for the research of one (2022 - one) member of the Society's National Board, Scientific Advisory Committee and Medical Advisory Committee. The Society adheres to a rigorous peer-review and evaluation process for its grant competitions. This process follows a strict confidentiality and conflict of interest policy founded on transparency, fairness and accountability. Payments for awarded research grants are made to the university that the investigator is associated with and the disbursement of the funds is administered by the university.

#### 14. Revolving demand facility:

The Society obtained a revolving line demand facility on June 30, 2015, subsequently amended February 22, 2018, April 17, 2020 and September 22, 2021, of \$1,500,000 available by way of Risk Based Pricing ("RBP") based on loans and letters of credit. The maximum amount of the facility increased from \$1,500,000 to \$2,000,000 on September 22, 2021. The facility is due on demand and incurs interest calculated at the RBP rate plus 0.75% per annum. The amount outstanding under this facility at year end is nil (2022 - nil). The facility is secured by a first ranking security interest in all personal property, and a collateral mortgage in the amount of up to \$2,000,000 constituting a first fixed charge on the land and improvements located in Vancouver, British Columbia. The facility contains certain non-financial covenants which were met at March 31, 2023.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

### 15. Allocation of expenses:

The Society has allocated its common expenses as follows:

2023	Research	Programs and services	Building operation	Administration	Cost of raising funds	Total
Executive office <sup>(1)</sup> Scientific office <sup>(2)</sup>	\$ 40,149 128,368	\$ 562,092 200,780	\$ - -	\$ 39,933	\$ 160,598 -	\$ 802,772 329,148
Amortization of capital assets <sup>(3)</sup>	600	77,783	95,717	149,581	4,996	328,677

2022	Research	Programs and services	Building operation	Administration	Cost of raising funds	Total
Executive office <sup>(1)</sup> Scientific office <sup>(2)</sup> Amortization of capital assets <sup>(3)</sup>	\$ 29,544 116,412 683	\$ 413,619 182,081 60,038	\$ – 70,196	\$ 27,148 - 168,732	\$ 118,177 - 3,288	\$ 588,488 298,493 302,937

<sup>(1)</sup> Executive office expenses consist primarily of salaries and benefits and staff travel and meeting expenses of the National Office.

<sup>(2)</sup> Scientific office expenses consist primarily of research salaries and benefits and staff travel and meeting expenses of the National Office.

<sup>(3)</sup> Amortization of capital assets consists of amortization costs of assets across all divisions and the National Office.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 16. Risk management:

Risk management relates to the understanding and active management of risks associated with all areas of the business and the associated operating environment. The Society has not observed any material changes in credit, interest rate, liquidity, market or foreign exchange risk as compared to the prior year.

Due to the COVID-19 pandemic impact on global economies, there continues to be material disruption which may continue to impact the risks described above. Management has taken measures to manage this risk and is actively monitoring the situation to minimize its impact to the Society, including the application to the Canada Emergency Wage Subsidy program and the Canada Emergency Rent Subsidy program. Included in support from government departments and agencies is nil (2022 - \$533,556) of wage subsidy related to the year ended March 31, 2023. Included in accounts receivable at year end is nil (2022 - \$30,614) related to the subsidies.

#### (a) Credit risk:

The Society's financial assets are cash and accounts receivable, both of which are subject to credit risk. The carrying amounts of financial assets on the statement of financial position represent the Society's maximum credit exposure at the statement of financial position date.

#### (b) Interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Changes in the prime interest rate will have a positive or negative impact on the Society's interest income. Such exposure will increase accordingly, should the Society maintain higher levels of investments in the future.

#### (c) Liquidity risk:

Liquidity risk is the risk that the Society will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Society manages its liquidity risk by monitoring its operating requirements. The Society prepares a budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 16. Risk management (continued):

In prior years the Society had in place a Reserve Policy that was intended to retain a minimum of cash and liquid investments/assets, adequate to cover outstanding accounts payable, restricted endowments and approximately three months of operating costs inclusive of payroll, rent and other normal expenses. This reserve represented the remaining balance of the appropriated reserve as disclosed in the statement of changes in resources. During 2021, the Board of Directors approved a new liquidity policy to replace the Reserve Policy. The new policy requires regular calculations of liquidity with a view to having six months of available operating expenses.

#### (d) Market risk:

Market risk arises as a result of trading in equity securities and fixed income securities. Fluctuations in the market expose the Society to a risk of loss. The Society mitigates this risk through controls to monitor and limit concentration levels.

#### (e) Foreign currency risk:

Foreign currency risk arises from gains and losses due to fluctuations in foreign currency exchange rates on the Society's foreign-denominated equity investments. The Society does not have significant transactions in foreign currencies or hold foreign currencies for a long period of time and, therefore, considers the exposure to foreign currency risk to be not significant.

(FORMERLY THE ARTHRITIS SOCIETY/LA SOCIÉTÉ D'ARTHRITE)

Notes to Financial Statements (continued)

Year ended March 31, 2023

#### 17. Alberta Charitable Fund-raising Act and Regulation:

Additional information to comply with the Disclosure Requirement of the Alberta Charitable Fund-raising Act and Regulation:

Disposition of contributions that is equal to or exceeds 10% of the gross contributions received were as follows:

Direct response Rest of campaigns Bequests Investment and miscellaneous income Support from government departments and agencies	\$ 7,251,251 6,457,228 7,386,952 2,153,518 5,743,460
	\$ 28,992,409

\$2,807,732 was paid as remuneration to employees whose principal duties involve fundraising.

\$714,077 was paid as remuneration to the fund-raising business, including any expenses or fees paid by the charitable organization on behalf of the fund-raising business or as reimbursement s to the fund-raising business.

#### 18. Comparative information:

Certain comparative information has been reclassified to conform with the financial statement presentation adopted in the current year.